Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system

In a substudy of a clinical trial, we assessed whether activation of latent human immunodeficiency virus (HIV) by the histone deacetylase inhibitor panobinostat had detrimental effects on the central nervous system (CNS). Adults infected with HIV received oral panobinostat 20 mg 3 times per week eve...

Full description

Saved in:
Bibliographic Details
Published in:Open forum infectious diseases 2015-01, Vol.2 (1), p.ofv037-ofv037
Main Authors: Rasmussen, Thomas A, Tolstrup, Martin, Møller, Holger Jon, Brinkmann, Christel R, Olesen, Rikke, Erikstrup, Christian, Laursen, Alex L, Østergaard, Lars, Søgaard, Ole S
Format: Article
Language:English
Subjects:
Brief Reports
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a substudy of a clinical trial, we assessed whether activation of latent human immunodeficiency virus (HIV) by the histone deacetylase inhibitor panobinostat had detrimental effects on the central nervous system (CNS). Adults infected with HIV received oral panobinostat 20 mg 3 times per week every other week for 8 weeks. In cerebrospinal fluid (CSF), we assayed panobinostat concentration, HIV RNA, and the level of neuroinflammatory or degenerative biomarkers in 11 individuals before and during study therapy. Neither panobinostat nor HIV RNA was detected in CSF. In addition, there was no change from baseline in CSF biomarkers. Thus, panobinostat administration was not associated with CNS adverse effects as assessed by CSF biomarkers.
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofv037